Silmitasertib

Phase 2Small molecule

SSenhwa Biosciences, Inc.

Silmitasertib is one of 68 small molecule programs targeting Neuroblastoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeuroblastomaRecruiting

COVID-19Active, not recruiting

NeuroblastomaPreclinical

Recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Calciferol

Alnylam Pharmaceuticals

Activella

Silmitasertib

SSenhwa Biosciences, Inc.

Phase 2

2 7

Achromycin V

WWyeth-Lederle Vaccines

Calcium

Selenium

SSWOG Cancer Research Network

Preclinical

1 10

Conventional

PPopulation Health Research Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2035

PreclinicalRecruiting

Neuroblastoma

NCT06541262

Clinical

Trials by Indication[1]

COVID-192 trials

Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)

Terminated·UUniversity of Arizona·Phase 2·NCT04668209·31 enrolled

Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

Completed·SSenhwa Biosciences, Inc.·Phase 2·NCT04663737·20 enrolled

Neuroblastoma1 trial

Phase I/II Study of Silmitasertib (CX-4945) in Combination With Chemotherapy in Children and Young Adults With Relapsed Refractory Solid Tumors

Recruiting·MMilton S. Hershey Medical Center·Preclinical·NCT06541262·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Silmitasertib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Silmitasertib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Silmitasertib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Senhwa Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSenhwa Biosciences, Inc.

Silmitasertib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2035

Trials by Indication[1]

COVID-192 trials

Neuroblastoma1 trial

References

Drug Info

Quick Facts

Related News